In this episode of The World of the API podcast, we have a chat with Teva Environmental, Social, Governance (ESG) experts, Itamar Schwartz and Adam Ajzensztejn about ESG in pharma. We talk about why ESG is such a buzz word at the moment, what impact the pharma industry can actually have, and what makes Teva's recent $5 billion sustainability-linked bond the first of its kind.
All content for The World of the API is the property of TAPI and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of The World of the API podcast, we have a chat with Teva Environmental, Social, Governance (ESG) experts, Itamar Schwartz and Adam Ajzensztejn about ESG in pharma. We talk about why ESG is such a buzz word at the moment, what impact the pharma industry can actually have, and what makes Teva's recent $5 billion sustainability-linked bond the first of its kind.
In this episode of The World of the API podcast, we have a chat with Teva Environmental, Social, Governance (ESG) experts, Itamar Schwartz and Adam Ajzensztejn about ESG in pharma. We talk about why ESG is such a buzz word at the moment, what impact the pharma industry can actually have, and what makes Teva's recent $5 billion sustainability-linked bond the first of its kind.
The World of the API
In this episode of The World of the API podcast, we have a chat with Teva Environmental, Social, Governance (ESG) experts, Itamar Schwartz and Adam Ajzensztejn about ESG in pharma. We talk about why ESG is such a buzz word at the moment, what impact the pharma industry can actually have, and what makes Teva's recent $5 billion sustainability-linked bond the first of its kind.
